VLS Valneva SE

Valneva SE Shareholding Declaration - March 2025

Valneva SE Shareholding Declaration - March 2025

VALNEVA

Declaration of shares and voting rights

March 31, 2025

__________________________________________________________________________________________

Company name: VALNEVA

Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)

Regulated market of Euronext Paris - Compartment B

Declaration date: April 3, 2025

Number of shares

composing the share capital of Valneva 		Total number of voting rights including suspended voting rights* Description of the change Date on which this change was recognized Total number of voting rights excluding suspended voting rights**
 162,521,524



 ordinary shares with a par value of €0.15 each 		178,409,478 Double voting rights granted on 1,456 ordinary shares Between March 2 & March 28, 2025 178,285,156

___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

** Net (or exercisable at a General Meeting) voting rights.

Attachment



EN
03/04/2025

Underlying

VLSValneva SE

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

 PRESS RELEASE
Free
VLS VALNEVA SE

Valneva SE Shareholding Declaration - March 2025

Valneva SE Shareholding Declaration - March 2025 VALNEVA Declaration of shares and voting rights March 31, 2025__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: April 3, 2025 Number of shares composing the share capital of Valneva Total number of voting rights including suspended voting rights* Description of the change Date on which this change was recognized Total numb...

18h / 29m 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

Déclaration d'actions et de droits de vote de la société Valneva SE - ...

Déclaration d'actions et de droits de vote de la société Valneva SE - Mars 2025 VALNEVA Déclaration d’actions et de droits de vote 31 mars 2025__________________________________________________________________________________________ Dénomination sociale : VALNEVAAdresse du siège social : 6 rue Alain Bombard, 44800 Saint-HerblainMarché réglementé Euronext Paris - Compartiment B Date de la déclaration : 3 avril 2025 Nombre d’actions composant le capital de Valneva Nombre total de droits de vote incluant les droits de vote suspendus* Origine de la variation Date à laquelle ce...

18h / 29m 1 EN
Oscar Haffen Lamm
  • Oscar Haffen Lamm
VLS VALNEVA SE

Valneva: EU approves label extension to adolescents for Ixchiq

Valneva announced that the EC has granted marketing authorization in EU for Ixchiq in individuals aged >12y.o, marking an important step in line with the label extension strategy for the asset as well as allowing Valneva to close the gap on the label presented by Bavarian's Vimkunya (approved in

04/02/25 April 2, 2025 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolesc...

Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above With this extension, IXCHIQ®, the first vaccine against the chikungunya virus (CHIKV), is now available for administration for individuals 12 years of age and older in the European Union (EU). Saint Herblain (France), April 1, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Commission (EC) has granted marketing authorization in Europe for Valneva’s single-dose vaccine, IXCHIQ®, for the prevention of disease caused by the chikungunya virus ...

April 1, 2025 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

Valneva : le vaccin contre le chikungunya, IXCHIQ®, désormais autorisé...

Valneva : le vaccin contre le chikungunya, IXCHIQ®, désormais autorisé chez les adolescents dans l'UE Avec cet élargissement d’indication, IXCHIQ®, le premier vaccin autorisé au monde contre le virus du chikungunya (CHIKV), est désormais disponible pour une administration dans l'Union Européenne (UE) chez les personnes âgées de 12 ans et plus. Saint Herblain (France), le 1er avril 2025 – (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui que la Commission Européenne (CE) a accordé une autorisation de mise sur le marché à IXCHIQ®, le vaccin à...

April 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch